EU MDR One Year Out: Reg Demands Forcing European Business Closures
Executive Summary
The impact of high regulatory demands on the innovation potential of medtech companies in Europe was a sub-theme of last week’s MedTech Forum in Paris. But it’s not a theoretical risk, for coinciding with the Forum was a decision by Swiss company Jossi Holding to close its orthopedics subsidiary.
You may also be interested in...
EU Officially Designates Second Notified Body Under The MDR: TÜV SÜD Enters Center Stage
TÜV SÜD, headquartered in Germany, is the second notified body to be officially designated under the EU MDR. Is this good news going to significantly lessen medtech industry’s concerns over delays in accessing the new, tougher regulatory system for medical technology, with time running seriously short?
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.